A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases
出版年份 2023 全文链接
标题
A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases
作者
关键词
-
出版物
EBioMedicine
Volume 90, Issue -, Pages 104539
出版商
Elsevier BV
发表日期
2023-04-01
DOI
10.1016/j.ebiom.2023.104539
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Discovery of a Conditionally Activated IL-2 that Promotes Antitumor Immunity and Induces Tumor Regression
- (2022) Christopher J. Nirschl et al. Cancer Immunology Research
- Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors
- (2022) Amanda M. Nash et al. Science Advances
- Organ-specific response after low-dose interleukin-2 therapy for steroid refractory chronic Graft-versus-Host Disease
- (2022) Haesook T Kim et al. Blood Advances
- Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1.
- (2022) Ulka N. Vaishampayan et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells
- (2022) Laura Codarri Deak et al. NATURE
- Interleukin-2–based therapies in cancer
- (2022) Miro E. Raeber et al. Science Translational Medicine
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
- (2021) Matthew J Page et al. BMJ-British Medical Journal
- Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases
- (2021) Hanna Graßhoff et al. Frontiers in Immunology
- 906P Simlukafusp α and cetuximab combination in patients with recurrent, unresectable or metastatic squamous cell carcinoma of the head and neck
- (2021) A.R. Hansen et al. ANNALS OF ONCOLOGY
- Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
- (2021) Adi Diab et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized phase Ib study to evaluate safety, pharmacokinetics and therapeutic activity of simlukafusp α in combination with atezolizumab ± bevacizumab in patients with unresectable advanced/ metastatic renal cell carcinoma (RCC) (NCT03063762).
- (2021) Jose Luis Perez-Gracia et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical activity and safety of simlukafusp alfa, an engineered interleukin-2 variant targeted to fibroblast activation protein-α, combined with atezolizumab in patients with recurrent or metastatic cervical cancer.
- (2021) Antoine Italiano et al. JOURNAL OF CLINICAL ONCOLOGY
- Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2.
- (2021) Omid Hamid et al. JOURNAL OF CLINICAL ONCOLOGY
- An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism
- (2021) Jerod L. Ptacin et al. Nature Communications
- A Phase I Trial of the Antibody-Cytokine Fusion Protein F16IL2 in Combination with Anti-CD33 Immunotherapy for Posttransplant AML Relapse
- (2021) Andrew F. Berdel et al. BLOOD
- CUE-101, a Novel HPV16 E7-pHLA-IL-2-Fc Fusion Protein, Enhances Tumor Antigen Specific T Cell Activation for the Treatment of HPV16-Driven Malignancies
- (2020) Steven N Quayle et al. CLINICAL CANCER RESEARCH
- Defining the Threshold IL-2 Signal Required for Induction of Selective Treg Cell Responses Using Engineered IL-2 Muteins
- (2020) Aazam Ghelani et al. Frontiers in Immunology
- Interleukin-2 signals converge in a lymphoid–dendritic cell pathway that promotes anticancer immunity
- (2020) Miro E. Raeber et al. Science Translational Medicine
- Toxicity of L19-Interleukin 2 Combined with Stereotactic Body Radiation Therapy: A Phase 1 Study
- (2020) Evert Jan Van Limbergen et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer
- (2020) Dilara Sahin et al. Nature Communications
- De novo design of potent and selective mimics of IL-2 and IL-15
- (2019) Daniel-Adriano Silva et al. NATURE
- A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
- (2019) Salah-Eddine Bentebibel et al. Cancer Discovery
- Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
- (2019) Jing He et al. ANNALS OF THE RHEUMATIC DISEASES
- A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients
- (2019) Benjamin Weide et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease
- (2018) Laurence B. Peterson et al. JOURNAL OF AUTOIMMUNITY
- Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
- (2017) Christian Klein et al. OncoImmunology
- NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
- (2016) D. H. Charych et al. CLINICAL CANCER RESEARCH
- TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial
- (2016) Elisabeth Quoix et al. LANCET ONCOLOGY
- Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2
- (2016) N. Arenas-Ramirez et al. Science Translational Medicine
- Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE
- (2015) Jens Y Humrich et al. ANNALS OF THE RHEUMATIC DISEASES
- Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study
- (2015) Riccardo Danielli et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes
- (2015) Aixin Yu et al. DIABETES
- Interleukin-2 Activity Can Be Fine Tuned with Engineered Receptor Signaling Clamps
- (2015) Suman Mitra et al. IMMUNITY
- NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy
- (2015) Michel M van den Heuvel et al. Journal of Translational Medicine
- Interleukin-2: Biology, Design and Application
- (2015) Natalia Arenas-Ramirez et al. TRENDS IN IMMUNOLOGY
- The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer
- (2015) Chiara Catania et al. Cell Adhesion & Migration
- IL-2: The First Effective Immunotherapy for Human Cancer
- (2014) S. A. Rosenberg JOURNAL OF IMMUNOLOGY
- Phase II trial of hu14.18-IL2 for patients with metastatic melanoma
- (2012) Mark R. Albertini et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours
- (2012) Silke Gillessen et al. EUROPEAN JOURNAL OF CANCER
- Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
- (2012) Aron M. Levin et al. NATURE
- Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264-272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies
- (2011) M. N. Fishman et al. CLINICAL CANCER RESEARCH
- A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma
- (2011) T. K. Eigentler et al. CLINICAL CANCER RESEARCH
- A Low-Toxicity IL-2-Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity
- (2011) S. D. Gillies et al. CLINICAL CANCER RESEARCH
- Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial
- (2011) Elisabeth Quoix et al. LANCET ONCOLOGY
- Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis
- (2011) David Saadoun et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
- (2011) John Koreth et al. NEW ENGLAND JOURNAL OF MEDICINE
- The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma
- (2010) Manfred Johannsen et al. EUROPEAN JOURNAL OF CANCER
- Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study
- (2010) Suzanne Shusterman et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells
- (2010) C. Krieg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antibody-Mediated Delivery of Interleukin-2 to the Stroma of Breast Cancer Strongly Enhances the Potency of Chemotherapy
- (2008) J. Marlind et al. CLINICAL CANCER RESEARCH
- MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure
- (2008) R. Dreicer et al. INVESTIGATIONAL NEW DRUGS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started